

RDV LICENSE AGREEMENT

This RDV LICENSE AGREEMENT (the “**Agreement**”) is made as of May 29, 2020 (the “**Effective Date**”) by and between **Gilead Sciences, Inc.** a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, California 94404, USA (“**Gilead**”), and **Syngene International Limited**, a Company incorporated under the laws of India and having a registered office at Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bengaluru 560 099, India (“**Licensee**”). Gilead and Licensee may each be referred to herein as a “**Party**” or collectively as the “**Parties**.”

RECITALS

WHEREAS, Gilead wishes to facilitate access to its proprietary compound remdesivir to treat patients with coronavirus disease 2019 (“**COVID-19**”) in 127 countries, as identified in this Agreement, via certain non-exclusive licenses to Licensee with respect to the manufacture and sale of remdesivir and product incorporating remdesivir; and

WHEREAS, Licensee wishes to obtain such non-exclusive licenses to facilitate patient access to Product incorporating remdesivir in such countries, all as more fully described in this Agreement below.

NOW, THEREFORE, in consideration of the mutual covenants set forth herein and other good and valuable considerations, the receipt of which is hereby acknowledged, the Parties hereto mutually agree as follows:

CONFIDENTIAL

IN WITNESS WHEREOF, the Parties hereto have executed this RDV License Agreement as of the Effective Date.

GILEAD:

Gilead Sciences, Inc.


By 
Name: Brett Pletcher
Title: EVP, Corporate Affairs & General Counsel

LICENSEE:

Syngene International Limited

DocuSigned by:

2757BDE1CFAC490...
By _____
Name: Manoj Gupta
Title: General Manager - Finance

DocuSigned by:

NK